Return Peptide Library
Carfilzomib
CLevel 1 evidenceCarfilzomib
Other/Research
Basic Information
Categories
Proteasome Inhibitors/Peptide Epoxyketones
Overview
FDA approves second-generation irreversible epoxomicin-derived proteasome inhibitor for relapsed/refractory multiple myeloma.
Efficacy Rating
FDA-approved, Oncology, Peptidomimetics
Evidence Level
Class C
Evidence Type
No data available
Confidence
No data available
China Regulatory Status
Cosmetic Ingredient Directory
No data available
Food/Supplements
No data available
Medicine
No data available
Similar Peptide Recommendations
Disclaimer
The content on this platform is for educational and informational purposes only and does not constitute medical advice, formulation guidance, or a guarantee of regulatory compliance. All efficacy claims are labeled with their evidence level; please consult a professional before making any decisions.